Skip to main content
Terug
SHPHF logo

Sihuan Pharmaceutical Holdings Group Ltd.

Datakwaliteit: 100%
Overbought
SHPHF
OTC Healthcare Drug Manufacturers - Specialty & Generic
€ 0,19
▲ € 0,02 (9,68%)
Marktkapitalisatie: 1,71B
Dagbereik
€ 0,19 € 0,19
52-Weeksbereik
€ 0,05 € 0,21
Volume
300
50D / 200D Gem.
€ 0,18 / € 0,12
Vorige Slotkoers
€ 0,19

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -7,9 0,4
P/B 0,4 2,9
ROE % -4,9 3,8
Net Margin % -11,4 3,9
Rev Growth 5Y % -6,3 10,0
D/E 0,2 0,2

Belangrijkste Punten

Revenue declined -6,28% annually over 5 years
Debt/Equity of 0,22 — conservative balance sheet
Generating 57,51M in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 8,46%
Capital efficient — spends only 9,80% of revenue on capex

Groei

Revenue Growth (5Y)
-6,28%
Revenue (1Y)2,18%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-4,92%
ROIC-1,94%
Net Margin-11,40%
Op. Margin-7,27%

Veiligheid

Debt / Equity
0,22
Current Ratio1,73
Interest Coverage-0,50

Waardering

P/E Ratio
-7,87
P/B Ratio0,39
EV/EBITDAN/A
Dividend Yield0,05%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 2,18% Revenue Growth (3Y) -6,64%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -6,28% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,90B Net Income (TTM) -216,66M
ROE -4,92% ROA -2,06%
Gross Margin 65,32% Operating Margin -7,27%
Net Margin -11,40% Free Cash Flow (TTM) 57,51M
ROIC -1,94% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,22 Current Ratio 1,73
Interest Coverage -0,50 Dividend Yield 0,05%
Valuation
P/E Ratio -7,87 P/B Ratio 0,39
P/S Ratio 0,90 PEG Ratio -0,05
EV/EBITDA N/A Dividend Yield 0,05%
Market Cap 1,71B Enterprise Value -942,07M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 1,90B 1,86B 2,18B 3,04B 2,46B
Net Income -216,66M -54,02M -1,91B 416,51M 473,38M
EPS (Diluted) -0,02 -0,01 -0,21 0,04 0,05
Gross Profit 1,24B 1,30B 1,49B 2,43B 1,91B
Operating Income -138,13M 161,70M -1,83B 771,95M 787,13M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 10,53B 11,54B 12,14B 14,50B 13,04B
Total Liabilities 5,58B 6,40B 6,50B 5,35B 3,10B
Shareholders' Equity 4,37B 4,43B 4,74B 8,28B 9,19B
Total Debt 974,01M 1,26B 1,29B 1,08B 755,05M
Cash & Equivalents 3,62B 3,89B 3,83B 5,68B 4,60B
Current Assets 5,72B 6,20B 6,55B 7,74B 6,40B
Current Liabilities 3,31B 4,11B 2,53B 2,50B 2,44B

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#204 of 820
56

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026